Study of a new drug combination for relapsed lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of drugs for people with a type of lymphoma (diffuse large B-cell lymphoma) that has come back or not responded to treatment. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have diffuse large B-cell lymphoma that is CD20 positive and has returned or not responded to treatment.
- You are between 20 and 75 years old.
- You have at least one measurable tumor.
- You are able to care for yourself (ECOG performance status 0-2).
- You have recovered from side effects of previous treatments, and it has been at least 3 weeks since chemotherapy or 4 weeks since radiation.
- Your kidney, liver, and bone marrow function are adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs for people with a type of lymphoma called diffuse large B-cell lymphoma that has either come back early or never fully responded to first treatment. The goal is to see if this drug combination can help control the lymphoma.
This trial tests a combination of three drugs (poseltinib, rituximab, and lenalidomide) for people with primary central nervous system lymphoma that has come back or not responded to earlier treatment. The goal is to see if this new mix can help control the disease.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests a new combination of drugs (tafasitamab + lenalidomide + gemcitabine + oxaliplatin) against a standard combination (rituximab + gemcitabine + oxaliplatin) for people with DLBCL that has returned or stopped responding to prior therapy. The goal is to see if the new combination works better.
This trial tests different combinations of targeted drugs and chemotherapy for people newly diagnosed with a type of lymphoma called DLBCL. It aims to find which combination is more effective and safer.
This trial is testing two drugs, pembrolizumab and ruxolitinib, together for people with certain types of lymphoma that have come back or not responded to at least one prior treatment. The goal is to see if this combination can help control the lymphoma.
Hear when a new Refractory Diffuse Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.